about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

No­vo Nordisk's pick for new chair­man sig­nals its on­go­ing pur­suit of M&A deals

8 years ago
People
Deals

Shake­up at Chi­na FDA af­ter chief vaults to the helm of a reg­u­la­to­ry um­brel­la group, new agency head named

8 years ago
People
China

As­traZeneca touts a fresh cut of Farx­i­ga da­ta tar­get­ing di­a­betes pa­tients with chron­ic kid­ney dis­ease

8 years ago
R&D

Ho­mol­o­gy, Unum set IPO terms; Knight pays Arde­lyx $19M for tena­panor rights in Cana­da

8 years ago
News Briefing

Long­time R&D chief Bischof­berg­er leaves Gilead; No­var­tis op­er­a­tions chief heads out; Astel­las taps Bar­ret­to-Ko to run ...

8 years ago
Peer Review

No­var­tis CEO Vas Narasimhan: We can do bet­ter at R&D, but we need FDA’s help; J&J gets $2.1B bid for LifeS­can

8 years ago
News Briefing

PureTech Health snags $100M to fund af­fil­i­ates; PolyPid takes a third stab at IPO

8 years ago
News Briefing

Bye CF­DA: Chi­na's drug reg­u­la­tor to take new shape in ma­jor gov­ern­ment re­struc­tur­ing

8 years ago
China

Te­va calls off CGRP drug dis­cov­ery and de­vel­op­ment pact, re­turns pre­clin­i­cal as­set to So­sei

8 years ago
Pharma

Op­er­a­tions head Wyss ex­its No­var­tis, giv­ing way to new struc­ture and a string of pro­mo­tions

8 years ago
People

Out­sourc­ing vet­er­an Jamie Mac­don­ald takes the helm at Parex­el; CSO Rosana Kapeller ex­its Nim­bus

8 years ago
Peer Review

Hua Med­i­cine plans to join trendy Hong Kong IPO club, pitch­ing an of­fer­ing of up to $400M -- re­ports

8 years ago
Financing
China

Nim­bus found­ing CSO Rosana Kapeller leaves to ex­plore ex­ec role; AI start­up BioX­cel pock­ets $60M from IPO

8 years ago
News Briefing

Fail­ure in piv­otal PhI­II brain can­cer tri­al drags Is­rael's VBL Ther­a­peu­tics down

8 years ago
R&D

Sanofi is jet­ti­son­ing its in­fec­tious dis­ease unit to Evotec — hand­ing over cash, staff and a pipeline

8 years ago
R&D
Pharma

'Rigged' pay­ment schemes by in­sur­ers and PBMs is block­ing the switch to biosim­i­lars, says FDA com­mis­sion­er

8 years ago
Pharma

#MeToo: ex-Sanofi em­ploy­ee gets un­fair dis­missal law­suit tossed, Ap­tose inks $125M BET in­hibitor deal

8 years ago
News Briefing

Ox­ford Vacmedix moves can­cer vac­cines for­ward with $12.5M from South Ko­rea, Chi­na

8 years ago
Financing
China

View­Point Ther­a­peu­tics gets $35M to ad­vance non-sur­gi­cal al­ter­na­tive for cataracts, pres­by­opia

8 years ago
Financing

Chi­nese med­i­cine play­er Tasly con­sid­ers Hong Kong IPO for its biotech arm: re­port

8 years ago
Financing
China

EpimAb nabs Bin Peng from NI­BR; Jef­frey Chodake­witz ex­its Ver­tex; Chris­tiana Sta­moulis is pres­i­dent at Unum

8 years ago
Peer Review

Ac­tivist in­vestor Alex Den­ner in the spot­light again as the Med­i­cines Com­pa­ny shrinks its board

8 years ago
People

With Resta­sis in its crosshairs, My­lan adds a Botox biosim with Re­vance; Ver­tex starts sec­ond PhI­II triple com­bo CF ...

8 years ago
News Briefing

It’s of­fi­cial: EMA to move in­to per­ma­nent Am­s­ter­dam premis­es in No­vem­ber ‘19 amid con­tin­ued protests from Italy

8 years ago
Pharma
First page Previous page 119120121122123124125 Next page Last page
A service from the Financial Times